Biotech & Drug DiscoveryKONEX 2512804 trials

AngioLab, Inc.

Official website

Founded in 1999, listed on KONEX in 2016, AngioLab develops new drugs and body-fat-reduction health functional foods.

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded on June 3, 1999 and listed on Korea's KONEX market on October 25, 2016, AngioLab, Inc. is a bio/new-drug company. Its business is centered on two lines: new drug development and body-fat-reduction health functional food products. It trades under ticker 251280 on KONEX and is classified in the bio/new-drug pharmaceutical category.

Clinical trials

data.go.kr

4 MFDS clinical trial authorisations · 2015–2019 (Phase 2 2 · Phase 2a 2)

Phase 2ALH-L1005정2019-12-24
3 trial sites
Phase 2aSMZ1정2019-11-08
1 trial site
Phase 2aSMZ1정2019-08-14
4 trial sites
Phase 2SMZ1정2015-06-29
12 trial sites

Not yet compiled: business overview · products · regulatory approvals · R&D. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

ABION Inc.85

KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

ProGen, Co,, LTD.85

KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®

GI Innovation Inc.85

Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

LigaChem Biosciences Inc.83

An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.

Sources and updates

Company basics: Korea Exchange · DART
Business content: Compiled from disclosure filings
AI visibility: Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition